GINECO prospective non-interventional PROSPECTYON study: Trabectedin plus pegylated liposomal doxorubicin for platinum-sensitive recurrent ovarian cancer

Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice. Patients and Methods: Patients with ROC after at least one platinum-based regimen received 1.1 mg/m²trabectedin plus 30 mg/m²PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)]. Results: Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups. Conclusion: Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.